Frost & Sullivan

MARCH 22, 2024

As of April 2023, the global pharmaceutical R&D pipeline has over 6000 molecules in active clinical development phase, showing a 5.8% However, the pharma/biopharma industry shows overall stagnant R&D activity. growth from 2023 to 2024. What is driving transformation in the pharma industry? increase from 2022.

Ecosystems 52

Ecosystems Biopharma Biotech Contract research organization 52

Frost & Sullivan

APRIL 25, 2023

April 25, 2023 – Frost & Sullivan researched the contract research organizations industry and, based on its analysis results, recognizes Emmes with the 2023 Global Competitive Strategy Leadership Award. years, to become a truly global company with a diverse mix of public sector and biopharma clients.

Biopharmaceuticals 52

Biopharmaceuticals Biopharma Biotechnology Contract research organization 52

IBM Business Partners

MAY 6, 2024

The FDA, in its May 2023 draft guidance, backed the adoption of DCTs across drugs, biologics and medical devices , highlighting their merits such as enhanced patient convenience, diminished caregiver burden, broader access to varied demographics, amplified trial productivity, and support for research on rare or mobility-restricted patient groups.

Partnering capability and readiness 57

Partnering capability and readiness Biopharma Contract research organization Collaboration 57